Pfizer Inc. (PFE)

Market Cap	140.88B
Revenue (ttm)	59.38B
Net Income (ttm)	4.25B
Shares Out	5.67B
EPS (ttm)	0.74
PE Ratio	33.39
Forward PE	10.13
Dividend	$1.68 (6.76%)
Ex-Dividend Date	Nov 8, 2024

Volume	50,581,350
Open	24.97
Previous Close	24.80
Day's Range	24.70 - 25.25
52-Week Range	24.48 - 31.54
Beta	0.61
Analysts	Buy
Price Target	33.17 (+33.43%)
Earnings Date	Oct 29, 2024

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1849
• Employees: 88,000
• Stock Exchange: NYSE
• Ticker Symbol: PFE
• Website: https://www.pfizer.com

Financial Performance

In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.

Analyst Forecast

According to 13 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $33.17, which is an increase of 33.43% from the latest price.

Price Target

$33.17

(33.43% upside)

Analyst Consensus: Buy